Lab to Lives
A simple question started this show: How do we medicine from the lab to making a difference in people's lives as quickly as possible?
The answers are complex. Actual solutions are hard to come by. We want to distill ideas until we see actual impact in the industry.
Our three hosts all have backgrounds in life sciences and in improv comedy. Together, with their guests, they're on a mission to have conversations that can have an impact. And have some fun along the way.
Lab to Lives
Leif Kuse: Nudging the industry towards innovation with group purchasing for biotechs
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
This week we speak to Leif Kuse, who is Lead Trailblazer of Drug Development Outsourcing Disruption and CEO PHARALL.
We speak about group purchasing for biotechs in clinical trials. We start out by exploring how CRO contracting usually happens for biotechs, where clinical trials are typically outsourced to CROs.
Biotech outsourcing is especially tricky, because in especially smaller companies, there may not be competencies to handle a sudden increase of people working for the company by adding a partner to the organization.
There are several models for collaborating with vendors - from a turnkey project, where you just “hand over the key” to a vendor, and wait for the results - to a close explorative collaboration, where the partner is basically a part of your organization.
We discuss the difference in services and pricing that is on the table for big pharmaceutical companies and biotechs, exploring the dynamics of the market and collaboration models.
There is no ideal CRO for a biotech - it all depends on what is needed, and how a collaboration can be established. Leif provides examples of great collaborations between CROs and biotech companies - where processes, culture and contracts all meshed.
The patient stands to benefit from successful collaboration between sponsors and CROs. The trials can be executed more smoothly and drugs can make it to market more rapidly.
Lastly we discuss if the pharmaceutical value chain could be decentralized in general, with companies like PHARALL brokering different parts of the value chain into a coherent whole.
Guest:
Leif Kuse
https://www.linkedin.com/in/leif-kuse-32042411/
PHARALL
________
Reach out to Ivanna Rosendal
Join the conversation on our LinkedIn page
.png)
